Published in Women's Health Weekly, July 27th, 2006
"The magnitude of the survival benefit of taxanes as adjuvant chemotherapy for early breast cancer is still unclear. A pooled analysis of Phase III trials was performed to assess the advantages that adjuvant taxane chemotherapy has over standard chemotherapy," investigators in Italy reported.
"All Phase III trials were considered eligible," explained E. Bria and colleagues, Regina Elena Institute for Cancer Research. "A pooled analysis was accomplished and event-based relative risk ratios (RR) with 95% confidence intervals (95%...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly